Core Viewpoint - The National Medical Products Administration (NMPA) has officially approved the oral androgen receptor inhibitor (ARi) Nubeigo (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in adult patients, marking its third indication approval [1] Group 1 - Nubeigo has previously been approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients [1] - Nubeigo was also approved for use in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in adult patients [1] - The recent approval expands the therapeutic options available for mHSPC, indicating a growing recognition of the drug's efficacy [1]